82978
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 8
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.887452372
- umap2_2d
- -0.198246413
- umap1_3d
- 0.917419115
- umap2_3d
- 1.13921115
- umap3_3d
- 0.628249479
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.460
- MYOGENESIS+0.260
- APICAL_SURFACE+0.250
- NOTCH_SIGNALING+0.180
- ANGIOGENESIS+0.140
- INFLAMMATORY_RESPONSE+0.140
- WNT_BETA_CATENIN_SIGNALING+0.140
- APICAL_JUNCTION+0.120
- ESTROGEN_RESPONSE_EARLY+0.100
- COAGULATION+0.080
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.630
- PROTEIN_SECRETION-0.600
- MYC_TARGETS_V1-0.590
- MTORC1_SIGNALING-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.460
- DNA_REPAIR-0.430
- MYC_TARGETS_V2-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- MITOTIC_SPINDLE-0.400
- ANDROGEN_RESPONSE-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.931 |
| 2 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.924 |
| 3 | SRR1444876 | GTEX | — | 0.924 |
| 4 | SRR1468974 | GTEX | — | 0.916 |
| 5 | SRR1390582 | GTEX | — | 0.911 |
| 6 | SRR1375271 | GTEX | — | 0.910 |
| 7 | SRR8613808 | — | D | 0.910 |
| 8 | BS_9F09XV62 | low-grade glioma | — | 0.905 |
| 9 | C3N-00175 | — | cohortA1 | 0.905 |
| 10 | SRR1487825 | GTEX | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.460 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |